Combining this approach with PI3K inhibition, antagonism of the insulin pathway to reduce side effects, and PKC inhibitors could represent an exciting multimodal therapy that targets several key oncogenic pathways in DIPG. Here, PRRT2 is linked to diffuse intrinsic pontine glioma.